White Paper: Medical
A Faster Route to Custom-Design Molecular Diagnostic Instruments
SPONSORED BY: ![]()
This whitepaper delves into developing molecular diagnostics instruments, emphasizing the advantages of collaboration with experienced OEMs using platforms like Cavro® Omni Flex for efficient design and regulatory compliance. It highlights how such customizable and modular systems facilitate tailored solutions that meet specific laboratory needs, significantly reducing development cycles, enhancing diagnostic accuracy, and accelerating market deployment, all while maintaining high standards of reliability and efficiency.
Don't have an account?
Overview
The white paper discusses the complexities and critical considerations involved in developing molecular diagnostics instruments, emphasizing the importance of precise planning and execution. It highlights the choice between in-house development and partnering with an experienced Original Equipment Manufacturer (OEM) like Tecan, which can significantly influence the success of the project.
Molecular diagnostics are essential in modern healthcare, enabling the detection and measurement of DNA or RNA markers for disease diagnosis, pathogen identification, and patient health monitoring. The demand for high-throughput, state-of-the-art instruments is increasing due to technological advancements in this rapidly evolving field. These instruments must handle small sample volumes with high sensitivity and minimal risk of cross-contamination.
The paper introduces the Cavro Omni Flex, a modular liquid handling platform designed to accelerate the development of automated molecular diagnostics solutions. Its flexible design allows customization to meet specific assay needs, while its ease of integration with existing systems simplifies the development process. The Cavro Omni Flex is compliant with high-quality standards, including ISO 13485 and FDA regulations, which helps streamline regulatory approval and reduce time-to-market.
Additionally, the white paper outlines the critical needs of molecular diagnostics instruments, such as sensitivity, specificity, and accuracy, which are vital for correct disease diagnosis and treatment. While off-the-shelf platforms are available, many organizations opt for custom solutions tailored to their specific applications, despite the challenges involved in such development.
Ultimately, the paper advocates for the role of OEM developers in navigating the complexities of molecular diagnostics instrument development, emphasizing that partnering with experienced companies can lead to more efficient, reliable, and successful outcomes in delivering cutting-edge diagnostic tools to the market.